The Heart Rhythm Society (HRS) recently announced the late-breaking clinical trials sessions for the upcoming Heart Rhythm scientific sessions.

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced the recent publication of two documents in support of extended continuous ambulatory monitoring for arrhythmia detection.

Black people with atrial fibrillation (AF) experience vastly higher rates of serious coronary events, so it’s not surprising that a growing number of clinical studies are aggressively tackling the complex issues around the impact of race—as well as gender—on management and outcomes of the heart rhythm disorder.

Medtronic has signed a deal to operate the catheterization and electrophysiology laboratories at the University Hospitals Cleveland Medical Center in Cleveland.

Abbott and St. Jude Medical announced Oct. 18 that the companies agreed to sell a portion of their vascular closure and electrophysiology business for $1.12 billion to Terumo Corporation.

Trial results on same-day discharge for elective implantable cardioverter-defibrillator procedures may reassure centers, but whether the approach lowers cost is anyone’s guess.

July 13, 2016 — Stereotaxis, Inc., a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company’s Niobe ES remote magnetic navigation system as part of its vision to create a cutting-edge arrhythmia technology suite. 

Five electrophysiologists joined Cardiovascular Business editorial advisor Matthew R. Reynolds, MD, SM, for a discussion about how they will deliver quality care to a growing number of atrial fibrillation patients even as the U.S. healthcare system turns its focus from volume to value.